Cargando…
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment
Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 sub...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142839/ https://www.ncbi.nlm.nih.gov/pubmed/32296575 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372 |
_version_ | 1783519473823645696 |
---|---|
author | Zhang, Yuting Guoqiang, Liu Sun, Miaomiao Lu, Xin |
author_facet | Zhang, Yuting Guoqiang, Liu Sun, Miaomiao Lu, Xin |
author_sort | Zhang, Yuting |
collection | PubMed |
description | Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits. |
format | Online Article Text |
id | pubmed-7142839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-71428392020-04-15 Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment Zhang, Yuting Guoqiang, Liu Sun, Miaomiao Lu, Xin Cancer Biol Med Review Neutrophils, the most abundant leukocytes in human blood, are essential fighter immune cells against microbial infection. Based on the finding that neutrophils can either restrict or promote cancer progression, tumor-associated neutrophils (TAN) are classified into anti-tumor N1 and pro-tumor N2 subsets. One of the major mechanisms underlying the tumor-promoting function of N2-TANs is suppression of adaptive immune cells, in particular, cytotoxic T lymphocytes. Currently, no established methodologies are available that can unequivocally distinguish immunosuppressive TANs and granulocytic/polymorphonuclear myeloid-derived suppressor cells (G/PMN-MDSC). In view of the critical role of PMN-MDSCs in immune evasion and resistance to cancer immunotherapy, as established from data obtained with diverse cancer models, therapeutic strategies targeting these cells have been actively developed to enhance the efficacy of immunotherapy. Here, we have reviewed the available literature on strategies targeting PMN-MDSCs and summarized the findings into four categories: (1) depletion of existing PMN-MDSCs, (2) blockade of the development of PMN-MDSCs, (3) blockade of PMN-MDSC recruitment, (4) inhibition of immunosuppressive function. Owing to their high mobility to inflamed organs and ability to trespass the blood-brain barrier, neutrophils are outstanding candidate carriers in nanoparticle-based therapies. Another attractive application of neutrophils in cancer therapy is the use of neutrophil membrane-derived nanovesicles as a surrogate of extracellular vesicles for more efficient and scalable drug delivery. In the second part of the review, we have highlighted recent advances in the field of neutrophil-based cancer drug delivery. Overall, we believe that neutrophil-based therapeutics are a rapidly growing area of cancer therapy with significant potential benefits. Compuscript 2020-02-15 2020-02-15 /pmc/articles/PMC7142839/ /pubmed/32296575 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372 Text en Copyright: © 2020, Cancer Biology & Medicine http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Zhang, Yuting Guoqiang, Liu Sun, Miaomiao Lu, Xin Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title_full | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title_fullStr | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title_full_unstemmed | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title_short | Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
title_sort | targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142839/ https://www.ncbi.nlm.nih.gov/pubmed/32296575 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0372 |
work_keys_str_mv | AT zhangyuting targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment AT guoqiangliu targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment AT sunmiaomiao targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment AT luxin targetingandexploitationoftumorassociatedneutrophilstoenhanceimmunotherapyanddrugdeliveryforcancertreatment |